Real-World check: Asciminib's performance in Tough-to-Treat CML
NCT ID NCT07640750
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will follow about 98 adults with chronic myeloid leukemia who are taking asciminib after other treatments have stopped working. Researchers want to see how many patients achieve a major molecular response (a key sign of disease control) after two years. The goal is to understand how effective and tolerable asciminib is in real-world settings, outside of controlled clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- asciminib
- What this could lead to
- If successful, this study could confirm that asciminib is a reliable option for controlling CML when other treatments have failed.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. It is also relatively small (98 participants) and not yet recruiting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Can a smart tool keep watch on leukemia after treatment stops?
- Can donor immune cells tame stem cell transplant risks?
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Could bone marrow from deceased donors cure blood cancers?
- New hope for young adults with CML: asciminib under Real-World scrutiny